Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb CEO Jim Cornelius said the company has over $1.3 billion in its coffers to finance more deals with small drug developers.
That's despite it's recent buyout of Medarex for $2.1 billion. The company will "continue to aggressively pursue acquisitions, licensing deals and other partnerships," promised Cornelius.

Oct 23 · 12:31:00 PM · Source: Fierce Biotech
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto